Androgen receptor has potent anti-tumor activity in ER+ breast cancer

Reuters Health - 20/01/2021 -The androgen receptor acts as a potent tumor suppressor in estrogen-receptor-positive (ER+) breast cancer and could be harnessed as an alternative or additive treatment strategy, researchers say. The need for therapeutic strategies that go beyond endocrine therapy has "renewed interest" in androgen therapy, especially given that nearly all ER+ breast cancers express androgen receptor and nonvirilizing selective androgen receptor modulators are now clinically available, the researchers note in Nature Medicine. But the role of the androgen receptor in ER+ breast cancer is "controversial, constraining implementation of AR-directed therapies," they point out. Using cell-line and patient-derived models, Dr. Wayne Tilley of the University of Adelaide, in Australia, and colleagues show that androgen-receptor activation exerts potent anti-tumor activity in ER+ breast cancer, even those resistant to estrogen-receptor and CDK4/6 inhibitors....

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 20 January, 20211 February, 2021